Study of gene patterns for Rifampicin in LPA, which were discordant in CBNAAT in the state of Telangana, India

Abstract

Introduction: Among the first line drugs used for treatment of Drug Sensitive Tuberculosis, Rifampicin plays a crucial role. Hence it is important to know the resistance of Rifampicin using molecular technologies like CBNAAT and line probe Assay. However, a diagnostic dilemma occurs when there is discordance in result of rifampicin resistance at periphery and in higher laboratories like Intermediate Reference Laboratory (IRL). Aims and objectives: To study various patterns of Gene for rifampicin that is demonstrated in probes of Line Probe Assao for First line –Line Probe Assay, which showed discordance with CBNAAT at periphery. Methodology: A retrospective observational study was conducted from 1st January 2021 to 31st December 2021 for all those samples which showed rifampicin discordance. Result: A total of 203 results were found discordant in Rifampicin. The resolution for rifampicin discordance is resolved using the NAAT facility at (IRL). Most of the resolution occurred in concurrence with result of Rifampicin in field. Eight of them gave inconclusive results (MTB not detected) Conclusion: It is very important to understand the gene patterns in LPA for providing appropriate regimen to the patients.